Medicare Enrolled
Dr. Rambabu Tummala, MD
Medical Oncology · Leesburg, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Tummala from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Tummala? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Tummala
Dr. Rambabu Tummala is a medical oncology in Leesburg, FL, with 20 years in practice. Based on federal Medicare data, Dr. Tummala performed 115,068 Medicare services across 3,629 unique beneficiaries.
Between the years covered by Open Payments, Dr. Tummala received a total of $9,912 from 78 pharmaceutical and/or device companies across 489 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Tummala is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 22% volume in FL$ $9,912 industry payments
Medicare Practice Summary
Medicare Utilization ↗115,068
Medicare services
Top 22% in FL for medical oncology
3,629
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,753 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 37,740 | $0 | $4 |
| Pembrolizumab injection (Keytruda) | 23,400 | $43 | $137 |
| Denosumab injection (Prolia/Xgeva) | 14,580 | $18 | $51 |
| Anti-nausea injection (aprepitant) | 10,790 | $1 | $5 |
| Epoetin alfa injection (Procrit) for anemia | 10,060 | $6 | $23 |
| Dexamethasone injection (steroid) | 4,044 | $0 | $3 |
| Complete blood count (CBC) with differential | 2,938 | $8 | $29 |
| Blood draw (venipuncture) | 2,881 | $8 | $9 |
| Office visit, established patient (20-29 min) | 1,773 | $64 | $239 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,180 | $1 | $28 |
| Anti-nausea injection (ondansetron/Zofran) | 1,145 | $0 | $9 |
| Drug injection, under skin or into muscle | 876 | $10 | $69 |
| Injection of additional new drug or substance into vein | 643 | $11 | $61 |
| Office visit, established patient (30-39 min) | 545 | $97 | $339 |
| Administration of chemotherapy into vein, 1 hour or less | 532 | $95 | $378 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 339 | $1 | $6 |
| Injection, diphenhydramine hcl, up to 50 mg | 207 | $1 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 169 | $47 | $189 |
| Injection, zoledronic acid, 1 mg | 152 | $7 | $69 |
| New patient office visit (45-59 min) | 133 | $124 | $453 |
| Red blood count, automated test | 132 | $4 | $10 |
| Administration of chemotherapy into vein, each additional hour | 131 | $21 | $79 |
| Injection of drug or substance into vein | 122 | $28 | $156 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 120 | $17 | $59 |
| Administration of additional new drug or substance into vein, 1 hour or less | 114 | $48 | $178 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 85 | $22 | $84 |
| Initial hospital admission, moderate complexity | 43 | $103 | $377 |
| Automated urinalysis | 42 | $2 | $8 |
| Infusion, normal saline solution , 1000 cc | 37 | $2 | $7 |
| Infusion into a vein for hydration, each additional hour | 36 | $10 | $42 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 36 | $16 | $56 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 23 | $3 | $11 |
| Infusion into a vein for hydration, 31-60 minutes | 20 | $25 | $156 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
33.1% high complexity
59.3% medium
7.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$9,912
Total received (2018-2024)
Avg $1,416/year across 7 years
Top 43% in FL for medical oncology
78
Companies
489
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,322 (94.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$590 (6.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,144
2023$1,841
2022$1,742
2021$1,299
2020$631
2019$1,025
2018$1,230
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$920
Janssen Biotech, Inc.
$818
E.R. Squibb & Sons, L.L.C.
$674
Incyte Corporation
$477
Merck Sharp & Dohme LLC
$387
GENZYME CORPORATION
$380
Takeda Pharmaceuticals U.S.A., Inc.
$373
Amgen Inc.
$330
Celgene Corporation
$316
Seagen Inc.
$290
Lilly USA, LLC
$280
Genentech USA, Inc.
$277
AstraZeneca Pharmaceuticals LP
$231
PFIZER INC.
$220
Astellas Pharma US Inc
$213
Eisai Inc.
$212
Merck Sharp & Dohme Corporation
$179
Regeneron Healthcare Solutions, Inc.
$170
Daiichi Sankyo Inc.
$160
Gilead Sciences, Inc.
$159
Foundation Medicine, Inc.
$142
EMD Serono, Inc.
$138
Bayer HealthCare Pharmaceuticals Inc.
$132
SOBI, INC
$126
Pharmacyclics LLC, an AbbVie Company
$122
TerSera Therapeutics LLC
$111
Kite Pharma, Inc.
$103
ARRAY BIOPHARMA INC
$100
Alexion Pharmaceuticals, Inc.
$94
Pharmacyclics LLC, An AbbVie Company
$91
Myriad Genetic Laboratories, Inc.
$78
GlaxoSmithKline, LLC.
$76
BeiGene USA, Inc.
$73
Stemline Therapeutics Inc.
$68
Boehringer Ingelheim Pharmaceuticals, Inc.
$66
ABBVIE INC.
$64
Pharmacosmos Therapeutics Inc.
$64
Bayer Healthcare Pharmaceuticals Inc.
$63
AMAG Pharmaceuticals, Inc.
$59
PharmaEssentia USA Corporation
$54
G1 Therapeutics, Inc.
$53
Spectrum Pharmaceuticals Inc.
$50
TESARO, Inc.
$50
ADC Therapeutics America, Inc.
$44
MorphoSys, US Inc.
$40
Dova Pharmaceuticals
$40
Ipsen Biopharmaceuticals, Inc
$40
PUMA BIOTECHNOLOGY, INC.
$39
EISAI INC.
$39
TG THERAPEUTICS, INC.
$33
Sun Pharmaceutical Industries Inc.
$33
Agios Pharmaceuticals, Inc.
$32
Janssen Pharmaceuticals, Inc
$32
Genmab U.S., Inc.
$29
Puma Biotechnology, Inc.
$27
Tolmar, Inc.
$26
SUN PHARMACEUTICAL INDUSTRIES INC.
$26
Innate Pharma, Inc
$24
Tempus AI, Inc
$23
JAZZ PHARMACEUTICALS INC.
$23
SERVIER PHARMACEUTICALS LLC
$22
Array BioPharma Inc.
$21
RECORDATI_RARE_DISEASES_INC.
$21
Adaptive Biotechnologies Corporation
$21
Epizyme, Inc.,
$20
Apellis Pharmaceuticals, Inc.
$20
Taiho Oncology, Inc.
$20
Seattle Genetics, Inc.
$19
Rigel Pharmaceuticals, Inc.
$18
Mirati Therapeutics, Inc.
$18
Heron Therapeutics, Inc.
$17
GE HealthCare
$16
Kyowa Kirin, Inc.
$16
CTI BioPharma Corp.
$15
Karyopharm Therapeutics Inc.
$15
Global Blood Therapeutics, Inc.
$14
Sobi, Inc
$14
Clovis Oncology, Inc.
$14
Top 3 companies account for 24.3% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · AUGTYRO · Alecensa · Aliqopa · Avastin · BAVENCIO · BESREMI · BLENREP · BOSULIF · BRACAnalysis CDx · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · Braftovi · CALQUENCE · CEREZYME · COSELA · CYRAMZA · DARZALEX · DOPTELET · Doptelet · ELIGARD · ELIQUIS · ELITEK · ELZONRIS · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Empaveli · Enhertu · Epkinly · Erleada · FARESTON · FERAHEME · FOUNDATIONONE · FRUZAQLA · Folotyn · GAZYVA · GILOTRIF · IBRANCE · ICLUSIG · IDHIFA · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lumoxiti · MEKINIST · MONJUVI · MONOFERRIC · MVASI · NERLYNX · NINLARO · Neulasta · Nplate · Nubeqa · OJJAARA · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Odomzo · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PYRUKYND · Padcev · Perjeta · Polivy · Prolia · Quzyttir · REBLOZYL · ROLVEDON · RYDAPT · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SHINGRIX · SOLIRIS · SOMATULINE DEPOT · SUSTOL · SYLVANT · SYNAGIS · Somatuline Depot · Stivarga · TASIGNA · TAZVERIK · TECENTRIQ · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Trodelvy · UKONIQ · ULTOMIRIS · VENCLEXTA · VERZENIO · VONJO · VOTRIENT · Vanflyta · Vitrakvi · Vonjo · XALKORI · XARELTO · XOSPATA · XPOVIO · XT CDX · XTANDI · Xofigo · Xospata · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · Zoladex · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (94%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $9 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
7
Per 100K population
1.8
County median income
$69,956
Nearest hospital
VILLAGES REGIONAL HOSPITAL, THE
7.0 mi
7.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Tummala is a mixed practice specialist, with above-average Medicare volume (top 22% in FL), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Tummala experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Tummala performed 37,740 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Tummala receive payments from pharmaceutical companies?
Yes. Dr. Tummala received a total of $9,912 from 78 companies across 489 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Tummala's costs compare to other medical oncologys in Leesburg?
Dr. Tummala's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Tummala) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Leesburg
Browse medical oncologys in Leesburg ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology